This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the severe asthma treatment landscape. Topics covered include; Novartis announcing the results from the 'Still Fighting for Breath' survey which demonstrates that despite the widespread availability of oral and inhaled treatments, asthma still places a huge burden on the personal and professional lives of those living with the disease in Europe. Critically, data from the surveys shows that 94 percent of severe allergic asthma patients were unable to fully control their disease; AstraZeneca presenting data from the Phase III ZONDA trial, which demonstrated that adding benralizumab (a fully humanised anti-interleukin [IL]-5 monoclonal antibody) to standard of care allowed patients dependent on oral corticosteroids (OCS) to significantly reduce or discontinue steroids while maintaining asthma control. The trial achieved its primary efficacy endpoint, demonstrating a statistically significant and clinically relevant reduction in daily maintenance OCS use with two benralizumab dosing regimens compared with placebo, and also demonstrated significant outcomes for secondary endpoints; Teva presenting new data on Cinqair/Cinqaero (reslizumab), an anti-IL-5 mAb approved in the US and Europe as add-on maintenance treatment for patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype. New data comes from a post-hoc pooled analysis of the Phase III BREATH study, and studies on the efficacy of reslizumab in patients eligible for Xolair (omalizumab; Roche/Novartis).
Business Questions:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved